论文部分内容阅读
伊马替尼 (ｉｍａｔｉｎｉｂ)用于慢性髓性白血病 (ＣＭＬ)的急性发作、急性期或α干扰素治疗失败后的慢性期的治疗。药效学 伊马替尼为竞争性腺苷三磷酸 (ＡＴＰ)抑制剂 ,在ＡＴＰ结合部位阻断ＡＴＰ的结合 ,因而抑制酪氨酸激酶的活性。体外伊马替尼可抑制ＢＣＲ ＡＢＬ(异常
Imatinib is used in the treatment of acute episodes of chronic myeloid leukemia (CML), acute phase, or chronic phase after failure of alpha interferon therapy. Pharmacodynamics Imatinib is a competitive inhibitor of adenosine triphosphate (ATP), which blocks the binding of ATP at the ATP binding site and thus inhibits tyrosine kinase activity. In vitro imatinib inhibits BCR ABL (Abnormal